Xanthohumol

Xanthohumol at a Glance

Xanthohumol is the principal prenylated chalcone of hops, and its story is really about what happens to it after you drink it.

It isomerises to isoxanthohumol during brewing, and gut bacteria convert that into 8-prenylnaringenin — one of the most potent phytoestrogens known. So a modestly estrogenic beverage becomes considerably more so through microbial metabolism, and the compound consumed is not the compound acting.

Xanthohumol itself has a heavily studied preclinical metabolic and anticancer profile.

What It's Used For

Xanthohumol is the principal prenylated chalcone of hops (Humulus lupulus), and therefore occurs in small amounts in beer. Its story turns on two facts. First, its chemistry is transformative: xanthohumol isomerizes to the flavanone isoxanthohumol (notably during brewing, so beer is richer in isoxanthohumol) and is then converted by gut bacteria to 8-prenylnaringenin — the most potent known phytoestrogen — which is where its hormonal caution comes from, not the parent itself. Second, its pharmacology is real but preclinical: strong metabolic, anticancer and anti-inflammatory activity across cells and rodents ^{1,4Reference 1Girisa S et al. · 2021Xanthohumol from hop: hope for cancer prevention and treatmentView study →Reference 4Neumann HF et al. · 2022Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studiesView study →}, with completed human safety and pharmacokinetic trials but no efficacy trial ^{9,10Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →Reference 10Brehmer-Henkel S et al. · 2026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}, all limited by poor oral bioavailability ^{2Reference 2Harish V et al. · 2021Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targetsView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. The completed human work is safety/PK, not efficacy, so scores stay low by design. Each application links to its write-up.

01Metabolic / cardiometabolicShaky42%Large animal body + human PK/safety (not efficacy) ^{3,4,10Reference 3Costa R et al. · 2017AnimalXanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in miceView study →Reference 4Neumann HF et al. · 2022Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studiesView study →Reference 10Brehmer-Henkel S et al. · 2026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}

02AnticancerShaky30%Large preclinical in-vitro/rodent literature ^{1,2Reference 1Girisa S et al. · 2021Xanthohumol from hop: hope for cancer prevention and treatmentView study →Reference 2Harish V et al. · 2021Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targetsView study →}

03Anti-inflammatory / antioxidantShaky30%In-vitro + animal mechanism ^{1,12Reference 1Girisa S et al. · 2021Xanthohumol from hop: hope for cancer prevention and treatmentView study →Reference 12Zhu L et al. · 2023Xanthohumol protects against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathwayView study →}

04HepatoprotectiveShaky28%Rodent models, mechanistically coherent ^{11,12Reference 11Atteia HH et al. · 2023AnimalThe hepatic antisteatosis effect of xanthohumol in high-fat-diet-fed rats entails activation of AMPKView study →Reference 12Zhu L et al. · 2023Xanthohumol protects against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathwayView study →}

05AntimicrobialShaky22%In-vitro against gut anaerobes ^{6Reference 6Čermák P et al. · 2017Strong antimicrobial activity of xanthohumol and other hop derivatives on gut anaerobic bacteriaView study →}

Mechanisms

Pharmacokinetics

Load-bearing and the central limitation of the whole molecule. Xanthohumol has poor oral bioavailability from low aqueous solubility and extensive first-pass metabolism (glucuronidation/conjugation) ^{2,4Reference 2Harish V et al. · 2021Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targetsView study →Reference 4Neumann HF et al. · 2022Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studiesView study →}. It isomerizes to isoxanthohumol — notably during brewing, so beer carries more isoxanthohumol than xanthohumol ^{7Reference 7Stevens JF · 2004Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/15231405/View study →} — and isoxanthohumol is then O-demethylated by gut bacteria to 8-prenylnaringenin (8-PN), the potent phytoestrogen; this is the main dietary route to 8-PN, and interindividual gut-flora variation makes 8-PN yield highly variable ^{7Reference 7Stevens JF · 2004Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/15231405/View study →}. Formulation matters: micellization substantially raises Cmax and AUC in humans across an 86–172 mg range ^{10Reference 10Brehmer-Henkel S et al. · 2026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}. Reassuringly, a human hop-supplement probe study found no clinically significant effect on CYP2C9, 1A2, 2D6 or 3A4 ^{8Reference 8van Breemen RB et al. · 2020Pharmacokinetic interactions of a hop dietary supplement with drug metabolism in perimenopausal and postmenopausal womenView study →}.

Clinical trials

There is no completed human efficacy trial for any indication. The human data are pharmacokinetics, safety and one bioactivity readout: the XMaS Phase I trial found 24 mg/day of pure xanthohumol over 8 weeks safe and well-tolerated ^{9Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →}; a bioavailability RCT confirmed micellization improves absorption but found no acute effect of 172 mg on metabolic endpoints ^{10Reference 10Brehmer-Henkel S et al. · 2026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}; and a grant-funded metabolic-syndrome RCT (20/60 mg) has no indexed clinical-outcome publication and should be treated as unpublished, not as positive evidence. A Phase II XMaS trial in Crohn’s disease is protocol-registered.

Last checked: July 2026.

Toxicity & Safety

Xanthohumol itself is well tolerated, but its safety question belongs to a metabolite rather than the molecule — gut bacteria convert it onward to 8-prenylnaringenin, the most potent known phytoestrogen.

Safety at a Glance

✅ Low / no toxicity

• Safe in the Phase I trial. 24 mg/day for 8 weeks produced no serious adverse events, with wide preclinical safety margins.
• No clinically significant CYP effect. A human study found no meaningful impact on CYP2C9, 1A2, 2D6 or 3A4 from a hop supplement.
• Avoid in pregnancy and lactation. The 8-prenylnaringenin route is the reason.
• Hormone-sensitive conditions. Theoretical caution with hormone-sensitive therapy is warranted given the 8-PN pathway.
• Supplement safety not fully characterized. The estrogenic caution is inherited by concentrated doses rather than dietary ones.

Full Safety & Interactions Detail

Xanthohumol has generally low toxicity — it has been consumed in small amounts via beer for centuries, and 24 mg/day for 8 weeks was safe in the Phase I trial with no serious adverse events and wide preclinical safety margins ^{9Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →}.

The important nuance is that the estrogenicity concern is a metabolite story, not xanthohumol’s own: the parent chalcone is essentially non-estrogenic, and the hormonal risk is the gut-derived 8-prenylnaringenin via the isoxanthohumol pathway ^{7Reference 7Stevens JF · 2004Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/15231405/View study →} — a caution inherited by concentrated supplemental doses, and the reason supplement safety is “not fully characterized.” On interactions, a human study found no clinically significant CYP2C9/1A2/2D6/3A4 effect from a hop supplement ^{8Reference 8van Breemen RB et al. · 2020Pharmacokinetic interactions of a hop dietary supplement with drug metabolism in perimenopausal and postmenopausal womenView study →}, though theoretical caution with hormone-sensitive therapy is warranted given the 8-PN route.

Dosage

There is no established therapeutic dose, and nothing here is a recommendation. The human safety trial used 24 mg/day of pure xanthohumol over 8 weeks ^{9Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →}; pharmacokinetic studies used single doses of 86–172 mg (micellar formulation markedly improving absorption over native powder) ^{10Reference 10Brehmer-Henkel S et al. · 2026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}; and the grant-stage metabolic-syndrome trial used 20 mg and 60 mg once daily with unpublished outcomes. Dietary intake from beer is on the order of micrograms to low milligrams and delivers isoxanthohumol and 8-prenylnaringenin more than xanthohumol itself.

References

1. Girisa S, et al. (2021). Xanthohumol from hop: hope for cancer prevention and treatment. IUBMB Life. https://pubmed.ncbi.nlm.nih.gov/34170599/
2. Harish V, et al. (2021). Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targets. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/33923053/
3. Costa R, et al. (2017). Xanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice. Journal of Nutritional Biochemistry. https://pubmed.ncbi.nlm.nih.gov/28431322/
4. Neumann HF, et al. (2022). Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studies. Molecular Nutrition & Food Research. https://pubmed.ncbi.nlm.nih.gov/34967501/
5. Gómez-Zorita S, et al. (2024). Beneficial effects of xanthohumol on metabolic syndrome: evidence from in-vitro and animal-model studies. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/39596505/
6. Čermák P, et al. (2017). Strong antimicrobial activity of xanthohumol and other hop derivatives on gut anaerobic bacteria. APMIS. https://pubmed.ncbi.nlm.nih.gov/28960474/
7. Stevens JF, Page JE (2004). Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/15231405/
8. van Breemen RB, et al. (2020). Pharmacokinetic interactions of a hop dietary supplement with drug metabolism in perimenopausal and postmenopausal women. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/32285669/
9. Langley B, et al. (2021). Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trial. Molecular Nutrition & Food Research. https://pubmed.ncbi.nlm.nih.gov/33629812/
10. Brehmer-Henkel S, Diekmann C, Eickeler M, et al. (2026). The bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trial. Molecular Nutrition & Food Research. https://pubmed.ncbi.nlm.nih.gov/41723719/
11. Atteia HH, AlFaris NA, Alshammari GM, et al. (2023). The hepatic antisteatosis effect of xanthohumol in high-fat-diet-fed rats entails activation of AMPK. Foods. https://pubmed.ncbi.nlm.nih.gov/38231665/
12. Zhu L, Fan X, Cao C, et al. (2023). Xanthohumol protects against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathway. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/37406514/

View all 12 references▾